Related Experiment Video

Updated: Mar 28, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

12.0K

JNK pathway in osteosarcoma: pathogenesis and therapeutics

Yu-Sheng Li1, Zhen-Han Deng1, Chao Zeng1

  • 1a Department of Orthopaedics , Xiangya Hospital of Central South University , Changsha , China.

Journal of Receptor and Signal Transduction Research
|December 17, 2015
PubMed
Abstract

Insights

The c-Jun NH2-terminal kinase (JNK) pathway is crucial in osteosarcoma (OS) development. JNK inhibitors show promise in preclinical models, suggesting potential therapeutic applications for this aggressive bone cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • The c-Jun NH2-terminal kinase (JNK) is a mitogen-activated protein kinase involved in various cellular processes.
  • JNK signaling is implicated in multiple carcinogenic mechanisms.
  • Osteosarcoma (OS) is a common and aggressive bone malignancy.

Purpose of the Study:

  • To review recent findings on the association between the JNK pathway and osteosarcoma.
  • To explore the role of JNK signaling in OS pathogenesis and potential therapeutic strategies.

Main Methods:

  • Comprehensive literature search of databases including PubMed, Google Scholar, and MEDLINE.
  • Collection and analysis of relevant research papers on JNK signaling in OS.
  • Review of studies on JNK pathway components and their involvement in OS.

Main Results:

  • JNK plays a key role in osteoblast proliferation, differentiation, and apoptosis.
  • Chemical JNK inhibitors have demonstrated efficacy in reducing OS cell proliferation and metastasis in preclinical studies.
  • While JNK pathway components are identified and inhibitors show in vivo efficacy, clinical translation is pending.

Conclusions:

  • Targeting the JNK pathway with potent and selective inhibitors may offer novel therapeutic strategies for osteosarcoma.
  • JNK inhibition could potentially improve survival rates and quality of life for OS patients.
  • Further research is needed to translate JNK inhibitor efficacy into clinical practice for osteosarcoma treatment.
Keywords:
JNK inhibitorsc-Jun NH2-terminal kinase pathwaymatrix metalloproteinasemitogen-activated protein kinaseosteosarcoma

More Related Videos

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.8K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.4K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
8.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
10.9K